21 March 2022 ORYZON announces FDA approval of IND for FRIDA, a Phase Ib trial with iadademstat in R/R AML FLT3mut+ patients
11 January 2022 ORYZON announces new Senior VP of Clinical Development and Global Medical Affairs, continuing its expansion of US corporate activities
4 January 2022 ORYZON announces approval for Serbian arm of PORTICO, vafidemstat’s Phase IIb trial in Borderline Personality Disorder
13 December 2021 ORYZON at ASH-2021: iadademstat 36-month ALICE data demonstrate robust efficacy in combination with azacitidine in AML
22 November 2021 ORYZON announces new Global Chief Business Officer and expansion of US corporate activities
17 November 2021 ORYZON enrolls first patient in EVOLUTION, a Phase IIb clinical trial with vafidemstat in schizophrenia